US drug major Schering-Plough has received a "complete response" letter from the Food and Drug Administration for Zegerid (omeprazole) 20mg, which the firm wants approved as an over-ther-counter treatment of heartburn.
The firm says the FDA has undisclosed questions regarding the application and intends to work closely with the agency on a confidential basis to expeditiously address the issues.
The New Drug Application for the OTC drug was submitted by Schering-Plough in March 2008 under the terms of a license agreement with Santarus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze